PolyMedix, Inc. (PYMX.OB) Appoints Steffen Helmling as VP of Business Development
Yesterday, PolyMedix, Inc. announced the appointment of Steffen Helmling, Ph.D. as their new Vice President of Business Development. Dr. Helmling will be responsible for new development initiatives, such as partnering and licensing for PolyMedix's products in development. PolyMedix is a biotech company focused on developing new pharmaceuticals for the treatment of infectious diseases and cardiovascular disorders. PolyMedix's lead antibiotic, MX-30063, is in Phase 2 clinical trials, and its lead heptagonist compound, PMX-60056, has completed Phase 1 trials. Their PolyCides products are intended to be used as additives to such items as paints, plastic and textile to create self-sterilizing surfaces. Dr.…